RBD COVID-19 Immunity Test

Description

The spread of SARS-CoV-2 virus infection remains one of the major challenges to be addressed by healthcare professionals. Therefore, in addition to the importance of carrying out techniques aimed at detecting the virus (PCR and antigen test), it is necessary to continue developing and improving serological techniques capable of detecting specific antibodies, whose role is decisive in the development of immunity against the SARS-CoV-2 virus. At Eurofins Megalab, we remain committed to scientific innovation. That is why we are constantly working on and fine-tuning the latest techniques available on the market.

The SARS-CoV-2 S-RBD IgG test determines the quantification of IgG Antibodies directed against the Receptor Binding Domain (RBD) of the S1 subunit (spike), which plays an essential role in the binding of the viral particle to the host cell receptor. Due to this mechanism of action, we can consider these antibodies as neutralising antibodies (NAb), capable of preventing the virus from infecting a cell by neutralising or inhibiting its biological effect.

Aimed at detecting the antibodies that are generated following the COVID-19 vaccine

*Price exclusive to the online shop.